Second, therapeutic potential: targeting LST1 or its downstream MHC-I pathway may both alleviate chronic inflammation in T2DM and reverse immune suppression in ccRCC, providing a unified therapeutic strategy. The gene discussed is LST1; the disease is type 2 diabetes mellitus.